Project Summary
The Stemedica Regenerative Medicine Platform is added as its own TYGAN project, while remaining fully integrated into the Tygan University Hospitals ecosystem.
This project is positioned as the advanced regenerative medicine, cell therapy, biomanufacturing, cell banking, clinical-trial, and training platform that can operate as a separate commercial and IP workstream with its own governance, finances, diligence, and operating model.
Patent Acquisition & Control
The project is to be structured around Tygan acquiring, owning, or exclusively controlling the relevant patents and rights.
- Patent schedule and chain-of-title evidence.
- Assignment or exclusive licence agreements where outright ownership is not immediately available.
- Territorial rights for South Africa and future African expansion.
- Freedom-to-operate review and independent legal opinion.
- Clear separation between patent ownership and clinical treatment approval.
Separate Wing, Fully Integrated
Stemedica becomes a separate advanced medicine wing and national platform inside the hospital project.
It should not be hidden inside the general hospital budget. It should have its own project identity, leadership, funding package, IP controls, clinical governance, manufacturing plan, training plan, and trial network, while serving the hospital campuses.
- National regenerative medicine centre of excellence.
- Provincial treatment/trial nodes inside each hospital ecosystem.
- Private medical-tourism regenerative pathway where legally approved.
- Community access pathway through trials, grants, subsidy, and public/private partnerships.
cGMP, Cell Banking & Labs
The strategic value is manufacturing, cell banking, quality systems, and trial capability, not only treatment rooms.
- South African cGMP biomanufacturing hub.
- Cell bank, biobank, QA/QC, batch tracking, and chain-of-custody systems.
- Backup or disaster-recovery manufacturing/cell-storage site.
- Per-province preparation, receiving, storage, and follow-up lab capability.
- Integration with redundant data centres and POPIA-grade patient/research data controls.
Clinical Trial Network
The nine-province hospital footprint can become a controlled trial and real-world evidence platform.
All treatment areas referenced in the Stemedica source pack must be treated as evaluation and trial pathways until verified and approved. This includes neurological, cardiac, pulmonary, metabolic, orthopedic, retinal, wound, frailty, longevity, and rehabilitation areas.
- SAHPRA and ethics approval pathway.
- University research partnerships.
- Standard patient recruitment, consent, and monitoring.
- Independent data safety monitoring and adverse-event reporting.
Advanced Therapy Training Institute
The Stemedica platform should include a formal training institute.
- Physician and specialist training.
- Nursing and cell-therapy patient-care training.
- Lab technician and GMP cleanroom training.
- QA/QC, biobank, batch-control, and chain-of-custody training.
- Clinical trial coordinator, pharmacovigilance, ethics, POPIA, and data training.
Due Diligence Guardrails
This project must be written carefully until legal, medical, and regulatory diligence is complete.
- Verify current corporate status, representatives, patents, licences, trademarks, and IP ownership.
- Verify manufacturing licences, cGMP status, clinical trial status, publications, endpoints, and adverse events.
- Verify current commercial terms and South Africa/Africa rights.
- Confirm SAHPRA, ethics, HPCSA, GMP/GCP/GLP, POPIA, and consumer-product requirements.
- No unapproved treatment marketing or unverified medical claims.